ACC 007

Drug Profile

ACC 007

Alternative Names: ACC007

Latest Information Update: 13 Jun 2017

Price : $50

At a glance

  • Originator Jiangsu Aidea Pharmaceutical
  • Class Antiretrovirals
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 07 Jun 2017 Phase-I clinical trials in HIV infections (In volunteers) in China (PO) (ChiCTR-OIR17011584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top